CRNX vs DYN
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. DYN: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform.
Side-by-side fundamentals
| Metric | CRNX | DYN | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $83.52 | $25.18 | |
| Market cap as of 2026-08-03 | $8.8B | $4.7B | |
| PEG as of 2026-08-03 | -0.47 | n/a | |
| Net margin as of 2026-08-03 | -2747.2% | n/a | |
| Gross margin as of 2026-08-03 | +86.0% | n/a | |
| Operating margin as of 2026-08-03 | -3020.3% | n/a | |
| ROE as of 2026-08-03 | -44.0% | -58.3% | CRNX higher |
| ROA as of 2026-08-03 | -39.6% | -46.8% | CRNX higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.18 | CRNX lower |
| Revenue growth (YoY) as of 2026-08-03 | +2277.5% | n/a | |
| Beta as of 2026-08-03 | 1.10 | 1.79 | |
| 1-year return as of 2026-07-31 close | +192.1% | +155.6% | CRNX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.